Independent risk factors for the development of hepatocellular carcinoma (HCC) in 818 patients with HBeAg-negative chronic hepatitis B treated with nucleos(t)ide analogue(s) therapy starting with lamivudine monotherapy. Results of multivariable Cox regression analyses
| Independent risk factor | Chronic hepatitis B only | Cirrhosis | All patients | |||
| Adjusted HR (95% CI) | p Value | Adjusted HR (95% CI) | p Value | Adjusted HR (95% CI) | p Value | |
| Age | ||||||
| <50 years | 1 | 1 | ||||
| 50–60 years | 11.90 (1.49 to 95.17) | 0.020 | 1* | 17.05 (2.25 to 129.48) | 0.006 | |
| >60 years | 31.55 (4.05 to 245.42) | 0.001 | 3.04 (1.23 to 7.50) | 0.016 | 35.04 (4.69 to 261.60) | 0.001 |
| Gender | ||||||
| Female | 1 | 1 | 1 | |||
| Male | 5.11 (1.18 to 22.21) | 0.029 | 2.19 (0.73 to 6.60) | 0.163 | 2.92 (1.22 to 6.97) | 0.016 |
| Liver disease severity | NA | – | ||||
| Chronic hepatitis B only | 1 | |||||
| Cirrhosis | 1.98 (1.07 to 3.67) | 0.031 | ||||
| Compensated | 1 | |||||
| Decompensated | 2.39 (0.93 to 6.12) | 0.071 | ||||
| Virological remission under therapy | ||||||
| Yes | 1 | 1 | 1 | |||
| No | 6.23 (0.82 to 47.08) | 0.076 | 0.71 (0.28 to 1.81) | 0.474 | 1.30 (0.59 to 2.84) | 0.515 |
↵* For cirrhotic patients, cases ≤60 years were grouped together, as there was no HCC in cases <50 years and therefore HR with 95% CI could not be reliably estimated.
NA, not applicable.